Shares of Cybin Inc. (OTCMKTS:CYBN – Get Free Report) traded down 1.7% during trading on Friday . The company traded as low as $8.16 and last traded at $8.32. 436,714 shares traded hands during trading, an increase of 42% from the average session volume of 307,838 shares. The stock had previously closed at $8.46.
Cybin Stock Down 1.7%
The company has a market capitalization of $191.56 million, a PE ratio of -43.79 and a beta of 0.69. The business’s 50 day simple moving average is $7.85 and its 200 day simple moving average is $7.93.
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Further Reading
- Five stocks we like better than Cybin
- ETF Screener: Uses and Step-by-Step Guide
- Why Pure Storage Is a Core Investment for the AI Era
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban
- What Do S&P 500 Stocks Tell Investors About the Market?
- Unity’s New Ad Solutions Drive Stock to 52-Week High
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
